Published in J Invest Dermatol on January 18, 2007
Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med (2011) 1.81
A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). Discov Med (2011) 1.65
Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm (2015) 1.44
The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1. ASN Neuro (2011) 1.19
Therapeutic decisions in multiple sclerosis: moving beyond efficacy. JAMA Neurol (2013) 1.16
Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor κB (NF-κB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling. J Biol Chem (2012) 1.13
The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment. Handb Clin Neurol (2014) 1.11
Nrf2/ARE-mediated antioxidant actions of pro-electrophilic drugs. Free Radic Biol Med (2013) 1.09
Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2. Proc Natl Acad Sci U S A (2016) 1.02
Dimethyl fumarate, an immune modulator and inducer of the antioxidant response, suppresses HIV replication and macrophage-mediated neurotoxicity: a novel candidate for HIV neuroprotection. J Immunol (2011) 0.99
Dimethyl fumarate and monoethyl fumarate exhibit differential effects on KEAP1, NRF2 activation, and glutathione depletion in vitro. PLoS One (2015) 0.94
Effects of fumaric acids on cuprizone induced central nervous system de- and remyelination in the mouse. PLoS One (2010) 0.94
DMF inhibits PDGF-BB induced airway smooth muscle cell proliferation through induction of heme-oxygenase-1. Respir Res (2010) 0.93
Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm (2015) 0.91
Dimethyl fumarate protects pancreatic islet cells and non-endocrine tissue in L-arginine-induced chronic pancreatitis. PLoS One (2014) 0.90
Dimethyl fumarate induces necroptosis in colon cancer cells through GSH depletion/ROS increase/MAPKs activation pathway. Br J Pharmacol (2015) 0.88
Anti-inflammatory dimethylfumarate: a potential new therapy for asthma? Mediators Inflamm (2013) 0.86
Dimethyl fumarate restores apoptosis sensitivity and inhibits tumor growth and metastasis in CTCL by targeting NF-κB. Blood (2016) 0.83
Dimethyl fumarate-induced lymphopenia in MS due to differential T-cell subset apoptosis. Neurol Neuroimmunol Neuroinflamm (2017) 0.82
Lack of allergy to timothy grass pollen is not a passive phenomenon but associated with the allergen-specific modulation of immune reactivity. Clin Exp Allergy (2016) 0.79
Dimethyl fumarate ameliorates acute pancreatitis in rodent. Pancreas (2015) 0.79
Oxidative stress and sodium methyldithiocarbamate-induced modulation of the macrophage response to lipopolysaccharide in vivo. Toxicol Sci (2009) 0.79
Effects of fumarates on circulating and CNS myeloid cells in multiple sclerosis. Ann Clin Transl Neurol (2015) 0.78
Neither T-helper type 2 nor Foxp3+ regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity. J Neuroinflammation (2014) 0.78
Chemical proteomic map of dimethyl fumarate-sensitive cysteines in primary human T cells. Sci Signal (2016) 0.78
Dimethyl Fumarate Therapy Significantly Improves the Responsiveness of T Cells in Multiple Sclerosis Patients for Immunoregulation by Regulatory T Cells. Int J Mol Sci (2017) 0.77
Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis. CNS Drugs (2014) 0.77
Nuclear factor erythroid 2-related factor 2 is a critical target for the treatment of glucocorticoid-resistant lupus nephritis. Arthritis Res Ther (2016) 0.75
Dimethyl Fumarate and Monomethyl Fumarate Promote Post-Ischemic Recovery in Mice. Transl Stroke Res (2016) 0.75
NF-κB Pathways in the Pathogenesis of Multiple Sclerosis and the Therapeutic Implications. Front Mol Neurosci (2016) 0.75
Fumaric acid esters in dermatology. Indian Dermatol Online J (2011) 0.75
Modulation of PPARγ provides new insights in a stress induced premature senescence model. PLoS One (2014) 0.75
Analysis of IL-6, IL-1β and TNF-α production in monocytes isolated from multiple sclerosis patients treated with disease modifying drugs. J Syst Integr Neurosci (2017) 0.75
Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov (2011) 22.33
A call for transparent reporting to optimize the predictive value of preclinical research. Nature (2012) 14.63
IL-22 increases the innate immunity of tissues. Immunity (2004) 8.30
Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther (2002) 5.43
IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol (2006) 4.88
Cutting edge: immune cells as sources and targets of the IL-10 family members? J Immunol (2002) 3.63
Heat-shock proteins as activators of the innate immune system. Trends Immunol (2002) 2.96
IL-22 induces lipopolysaccharide-binding protein in hepatocytes: a potential systemic role of IL-22 in Crohn's disease. J Immunol (2007) 1.80
Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci U S A (2003) 1.71
The role of mitogen-activated protein kinase-activated protein kinase 2 in the p38/TNF-alpha pathway of systemic and cutaneous inflammation. J Invest Dermatol (2009) 1.53
Crowd sourcing in drug discovery. Nat Rev Drug Discov (2011) 1.51
Immunopathogenesis of psoriasis. Exp Dermatol (2007) 1.44
Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs. Exp Dermatol (2006) 1.41
Glucocorticoid therapy-induced skin atrophy. Exp Dermatol (2006) 1.40
Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol (2007) 1.39
Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends Mol Med (2005) 1.31
Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J Leukoc Biol (2008) 1.26
Dendritic polyglycerol sulfates as multivalent inhibitors of inflammation. Proc Natl Acad Sci U S A (2010) 1.22
The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis. Eur J Immunol (2009) 1.19
Biology of tumor necrosis factor-alpha- implications for psoriasis. Exp Dermatol (2004) 1.14
Immunoregulation through 1,25-dihydroxyvitamin D3 and its analogs. Curr Drug Targets Inflamm Allergy (2004) 1.12
NK cells stimulate proliferation of T and NK cells through 2B4/CD48 interactions. J Immunol (2004) 1.11
Heat shock protein 60 is released in immune-mediated glomerulonephritis and aggravates disease: in vivo evidence for an immunologic danger signal. J Am Soc Nephrol (2004) 1.07
Induction of Foxp3+ regulatory T cells with histone deacetylase inhibitors. Cell Immunol (2009) 1.02
Heme oxygenase-1 inhibits T cell-dependent skin inflammation and differentiation and function of antigen-presenting cells. Exp Dermatol (2007) 1.02
An aspirin-triggered lipoxin A4 stable analog displays a unique topical anti-inflammatory profile. J Immunol (2002) 1.01
Lipopolysaccharide-free heat shock protein 60 activates T cells. J Biol Chem (2004) 0.98
Expression profiling of IL-10-regulated genes in human monocytes and peripheral blood mononuclear cells from psoriatic patients during IL-10 therapy. Eur J Immunol (2004) 0.98
Dissociated glucocorticoid receptor ligands: compounds with an improved therapeutic index. Curr Opin Investig Drugs (2005) 0.96
A novel immunosuppressive 1alpha,25-dihydroxyvitamin D3 analog with reduced hypercalcemic activity. J Invest Dermatol (2002) 0.94
What makes a good drug target? Drug Discov Today (2011) 0.92
Immunomodulation by a novel, dissociated Vitamin D analogue. Exp Dermatol (2009) 0.92
Insight into the molecular mechanisms of glucocorticoid receptor action promotes identification of novel ligands with an improved therapeutic index. Exp Dermatol (2006) 0.92
Role of fucosyltransferases in leukocyte trafficking: major impact for cutaneous immunity. Trends Immunol (2003) 0.90
IL-10 protects monocytes and macrophages from complement-mediated lysis. J Leukoc Biol (2009) 0.90
Cytokine and anticytokine therapy in dermatology. Expert Opin Biol Ther (2003) 0.87
Expression of CD83 in the murine immune system. Med Microbiol Immunol (2003) 0.87
CCR4 and CCR10 ligands play additive roles in mouse contact hypersensitivity. Exp Dermatol (2008) 0.86
Fumaric acid esters are potent immunosuppressants: inhibition of acute and chronic rejection in rat kidney transplantation models by methyl hydrogen fumarate. Arch Dermatol Res (2002) 0.86
Techniques: species' finest blend--humanized mouse models in inflammatory skin disease research. Trends Pharmacol Sci (2004) 0.86
Cytokine and anti-cytokine therapies for psoriasis and atopic dermatitis. BioDrugs (2006) 0.85
Targeting leukocyte trafficking to inflamed skin: still an attractive therapeutic approach? Exp Dermatol (2007) 0.85
Test systems for the determination of glucocorticoid receptor ligand induced skin atrophy. Dermatoendocrinol (2011) 0.84
Inhibition of the IL-2-inducible tyrosine kinase (Itk) activity: a new concept for the therapy of inflammatory skin diseases. Exp Dermatol (2011) 0.82
Immunomodulation by interleukin-10 therapy decreases the incidence of relapse and prolongs the relapse-free interval in Psoriasis. J Invest Dermatol (2002) 0.82
[Founding the new German Skin Research Center]. J Dtsch Dermatol Ges (2007) 0.81
Grants4Targets - an innovative approach to translate ideas from basic research into novel drugs. Drug Discov Today (2010) 0.80
Comprehensive biomarker monitoring in cytokine therapy: heterogeneous, time-dependent, and persisting immune effects of interleukin-10 application in psoriasis. J Leukoc Biol (2008) 0.80
Selectin and selectin ligand binding: a bittersweet attraction. J Clin Invest (2003) 0.80
The glucocorticoid receptor as target for classic and novel anti-inflammatory therapy. Curr Drug Targets Inflamm Allergy (2004) 0.80
Superior nuclear receptor selectivity and therapeutic index of methylprednisolone aceponate versus mometasone furoate. Exp Dermatol (2007) 0.80
Persistent CMV infection correlates with disease activity and dominates the phenotype of peripheral CD8+ T cells in psoriasis. Exp Dermatol (2011) 0.80
Keratinocyte unresponsiveness towards interleukin-10: lack of specific binding due to deficient IL-10 receptor 1 expression. Exp Dermatol (2003) 0.79
What makes a good drug target? Drug Discov Today (2011) 0.78
RNA interference-mediated gene silencing in murine T cells: in vitro and in vivo validation of proinflammatory target genes. Cell Commun Signal (2008) 0.78
Animal models of T-cell-mediated skin diseases. Bioessays (2004) 0.77
Ultraviolet B radiation-mediated inhibition of interferon-gamma-induced keratinocyte activation is independent of interleukin-10 and other soluble mediators but associated with enhanced intracellular suppressors of cytokine-signaling expression. J Invest Dermatol (2003) 0.77
Cytokines as potential therapeutic targets for inflammatory skin diseases. Eur Cytokine Netw (2005) 0.75
Efomycine M: an inhibitor of selectins? Nat Med (2006) 0.75
Willingness to Donate Human Samples for Establishing a Dermatology Research Biobank: Results of a Survey. Biopreserv Biobank (2011) 0.75
Shortened treatment duration of glucocorticoid-induced skin atrophy in rats. Exp Dermatol (2011) 0.75
The immunological synapse: kinases in T cell signalling as potential drug targets. Immunol Lett (2006) 0.75
Biomarkers for intensive care medicine patients: the (stony) path into a bright future? Biomarkers (2011) 0.75
[New developments in the systemic treatment of psoriasis]. J Dtsch Dermatol Ges (2003) 0.75
Nuclear receptors: old targets, new opportunities. Curr Drug Targets Inflamm Allergy (2004) 0.75
Humanised mouse models in drug discovery for skin inflammation. Expert Opin Drug Discov (2006) 0.75